These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

1213 related articles for article (PubMed ID: 27250110)

  • 41. Bypassing multidrug resistance in human breast cancer cells with lipid/polymer particle assemblies.
    Li B; Xu H; Li Z; Yao M; Xie M; Shen H; Shen S; Wang X; Jin Y
    Int J Nanomedicine; 2012; 7():187-97. PubMed ID: 22275834
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Selection of P-Glycoprotein Inhibitor and Formulation of Combinational Nanoformulation Containing Selected Agent Curcumin and DOX for Reversal of Resistance in K562 Cells.
    Dash TK; Konkimalla VB
    Pharm Res; 2017 Aug; 34(8):1741-1750. PubMed ID: 28536971
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Bypassing multidrug resistant ovarian cancer using ultrasound responsive doxorubicin/curcumin co-deliver alginate nanodroplets.
    Baghbani F; Moztarzadeh F
    Colloids Surf B Biointerfaces; 2017 May; 153():132-140. PubMed ID: 28235723
    [TBL] [Abstract][Full Text] [Related]  

  • 44. The carotenoid fucoxanthin can sensitize multidrug resistant cancer cells to doxorubicin via induction of apoptosis, inhibition of multidrug resistance proteins and metabolic enzymes.
    Eid SY; Althubiti MA; Abdallah ME; Wink M; El-Readi MZ
    Phytomedicine; 2020 Oct; 77():153280. PubMed ID: 32712543
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Coformulation of doxorubicin and curcumin in poly(D,L-lactide-co-glycolide) nanoparticles suppresses the development of multidrug resistance in K562 cells.
    Misra R; Sahoo SK
    Mol Pharm; 2011 Jun; 8(3):852-66. PubMed ID: 21480667
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Co-Inhibition of P-gp and Hsp90 by an Isatin-Derived Compound Contributes to the Increase of the Chemosensitivity of MCF7/ADR-Resistant Cells to Doxorubicin.
    Abdalla AN; Di Stefano M; Poli G; Tuccinardi T; Bader A; Vassallo A; Abdallah ME; El-Readi MZ; Refaat B; Algarni AS; Ahmad R; Alkahtani HM; Abdel-Aziz AA; El-Azab AS; Alqathama A
    Molecules; 2021 Dec; 27(1):. PubMed ID: 35011321
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Indocyanine green/doxorubicin-encapsulated functionalized nanoparticles for effective combination therapy against human MDR breast cancer.
    Chen HH; Lu IL; Liu TI; Tsai YC; Chiang WH; Lin SC; Chiu HC
    Colloids Surf B Biointerfaces; 2019 May; 177():294-305. PubMed ID: 30771581
    [TBL] [Abstract][Full Text] [Related]  

  • 48. Charge-reversal-functionalized PLGA nanobubbles as theranostic agents for ultrasonic-imaging-guided combination therapy.
    Yang H; Shen X; Yan J; Xie X; Chen Z; Li T; Li S; Qin X; Wu C; Liu Y
    Biomater Sci; 2018 Aug; 6(9):2426-2439. PubMed ID: 30040100
    [TBL] [Abstract][Full Text] [Related]  

  • 49. A Y
    Wang Y; Jiang Z; Yuan B; Tian Y; Xiang L; Li Y; Yang Y; Li J; Wu A
    Biomater Sci; 2019 Nov; 7(11):4748-4757. PubMed ID: 31508613
    [TBL] [Abstract][Full Text] [Related]  

  • 50. Reversal of multidrug resistance by icaritin in doxorubicin-resistant human osteosarcoma cells.
    Wang ZD; Wang RZ; Xia YZ; Kong LY; Yang L
    Chin J Nat Med; 2018 Jan; 16(1):20-28. PubMed ID: 29425587
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Reversion of multidrug resistance in a chemoresistant human breast cancer cell line by β-elemene.
    Xu HB; Li L; Fu J; Mao XP; Xu LZ
    Pharmacology; 2012; 89(5-6):303-12. PubMed ID: 22573000
    [TBL] [Abstract][Full Text] [Related]  

  • 52. Amphiphilic Copolymeric Micelles for Doxorubicin and Curcumin Co-Delivery to Reverse Multidrug Resistance in Breast Cancer.
    Lv L; Qiu K; Yu X; Chen C; Qin F; Shi Y; Ou J; Zhang T; Zhu H; Wu J; Liu C; Li G
    J Biomed Nanotechnol; 2016 May; 12(5):973-85. PubMed ID: 27305819
    [TBL] [Abstract][Full Text] [Related]  

  • 53. Tumor delivery of liposomal doxorubicin prepared with poly-L-glutamic acid as a drug-trapping agent.
    Miatmoko A; Kawano K; Yoda H; Yonemochi E; Hattori Y
    J Liposome Res; 2017 Jun; 27(2):99-107. PubMed ID: 26982164
    [TBL] [Abstract][Full Text] [Related]  

  • 54. Drug resistance reversal activity of anticancer drug loaded solid lipid nanoparticles in multi-drug resistant cancer cells.
    Miao J; Du YZ; Yuan H; Zhang XG; Hu FQ
    Colloids Surf B Biointerfaces; 2013 Oct; 110():74-80. PubMed ID: 23711779
    [TBL] [Abstract][Full Text] [Related]  

  • 55. Reversal of P-glycoprotein-mediated multidrug resistance by guggulsterone in doxorubicin-resistant human myelogenous leukemia (K562/DOX) cells.
    Xu HB; Li L; Liu GQ
    Pharmazie; 2009 Oct; 64(10):660-5. PubMed ID: 19947169
    [TBL] [Abstract][Full Text] [Related]  

  • 56. Codelivery of Adriamycin and P-gp Inhibitor Quercetin Using PEGylated Liposomes to Overcome Cancer Drug Resistance.
    Yu J; Chen H; Jiang L; Wang J; Dai J; Wang J
    J Pharm Sci; 2019 May; 108(5):1788-1799. PubMed ID: 30610857
    [TBL] [Abstract][Full Text] [Related]  

  • 57. Development of stealth liposome coencapsulating doxorubicin and fluoxetine.
    Ong JC; Sun F; Chan E
    J Liposome Res; 2011 Dec; 21(4):261-71. PubMed ID: 21226547
    [TBL] [Abstract][Full Text] [Related]  

  • 58. Co-delivery of doxorubicin and RNA using pH-sensitive poly (β-amino ester) nanoparticles for reversal of multidrug resistance of breast cancer.
    Tang S; Yin Q; Zhang Z; Gu W; Chen L; Yu H; Huang Y; Chen X; Xu M; Li Y
    Biomaterials; 2014 Jul; 35(23):6047-59. PubMed ID: 24797883
    [TBL] [Abstract][Full Text] [Related]  

  • 59. Reversion of Multidrug Resistance by Co-Encapsulation of Doxorubicin and Metformin in Poly(lactide-co-glycolide)-d-α-tocopheryl Polyethylene Glycol 1000 Succinate Nanoparticles.
    Shafiei-Irannejad V; Samadi N; Salehi R; Yousefi B; Rahimi M; Akbarzadeh A; Zarghami N
    Pharm Res; 2018 Apr; 35(6):119. PubMed ID: 29671072
    [TBL] [Abstract][Full Text] [Related]  

  • 60. Design and synthesis of new potent N,N-bis(arylalkyl)piperazine derivatives as multidrug resistance (MDR) reversing agents.
    Dei S; Coronnello M; Bartolucci G; Manetti D; Romanelli MN; Udomtanakunchai C; Salerno M; Teodori E
    Eur J Med Chem; 2018 Mar; 147():7-20. PubMed ID: 29421572
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 61.